1055 reports of cone biopsy (between 2013 and 2015) had been screened for previus results of HPV detection. The aim of this study was to observe and evaluate the correlation between the reports of high-grade human papilloma virus and the reports of cone biopsy in follow-up.
Each histology report was compared with outcomes of high-risk HPV: HPV 16 and HPV 18 specific genotyping and the pooled result of HPV Types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (cobas® HPV Test; F.Hoffmann-La Roche AG). The reports of cone-biopsy were evaluated in four groups: negative for squamous intraepithelial lesions or malignancy (negative), low grade squamous intraepithelial lesions (LGSIL), high grade squamous intraepithelial lesions (HGSIL) and invasive carcinoma. The results of the comparison were evaluated as statistically significant at p <0,05 (NCSS Statistical Software).
342 women (average age 36,1 years) had been tested for high-risk HPV before. The average period between the last HPV typing and the conisation was 4,1 months. The report of cone biopsy was: 5,3% negative cases (18/342), 19,0% LGSIL cases (65/342), 74,3% HGSIL cases (254/342) and 1,5% cases of invasive carcinoma (5/342). 302 out of the 342 women with cone biopsy (88,3%) were positive according to the high-risk HPV test. There was a high statistically significant difference (p=0,00000; Chi -square test) between negative/positive HPV results in relation to the grade of cervical intraepithelial lesions in follow up. The distribution negative/positive HPV results in women with low grade squamous intraepithelial lesions was 19/46 compared to 14/240 negative/positive cases in women with high grade squamous intraepithelial lesions.
The different frequency of high risk HPV positivity in women with a cone biopsy report clearly reflect the correlation between the type of detected HPV and the grade of lesion in follow up. Women with low grade intraepithelial lesion were high-risk HPV positive in 70,8% cases (46/65). The percentage increases to 94,5% in women with high grade intraepithelial lesion (240/254). As expected all women with invasive carcinoma were high-risk HPV positive. Molecular biological testing for high-risk human papillomavirus provides information about the patient’s risk for developing cervical lesions in follow up.